Article

Helen Keller International wins award for its role in onchocerciasis

A winner has been announced for the latest Arab Gulf Programme for United Nations Development Organization prize. The blindness charity Helen Keller International (HKI) has won for its role in onchocerciasis (river blindness) control in 10 African countries.

Riyadh, Saudi Arabia and New York City-A winner has been announced for the latest Arab Gulf Programme for United Nations Development Organization prize. The blindness charity Helen Keller International (HKI) has won for its role in onchocerciasis (river blindness) control in 10 African countries.

The project was nominated by the United Nations Children's Fund and a judges’ committee composed of professional experts chose it from five nominated projects.

HKI aims to reach 102 million people at risk of onchocerciasis in Burkina Faso, Côte d’Ivoire, Cameroon, Democratic Republic of Congo, Guinea, Mali, Niger, Nigeria, Sierra Leone, and Tanzania.

Founded in 1915, HKI is among the oldest international non-profit organizations devoted to fighting and treating preventable blindness and malnutrition.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Parag Majmudar, MD, on bridging the gap between residency and real-world practice
Brett Bielory, MD, discusses his poster at the ASCRS annual meeting, which focuses on an under-diagnosed corneal pathology: neurotrophic keratitis.
(Image credit: Ophthalmology Times) Oluwatosin U. Smith talks Glaukomtecken
ASCRS 2025: Eva Kim, MD, discusses implantable collamer lenses and high myopia.
Abby Markward, MBA, and Hattie Hayes, editor of Ophthalmology Times Europe, discuss the ASCRS and ASOA meetings
Abby Markward discusses the ASCRS Foundation and the ASCRS Annual Meeting
(Image credit: Ophthalmology Times) Inside ASCRS 2025: Francis S. Mah, MD, takes the helm with a vision for research, education, and advocacy
Š 2025 MJH Life Sciences

All rights reserved.